



Final Appraisal Recommendation

Valganciclovir (Valcyte[®]) tablets

**Submission by:
Roche Products Ltd**

Advice No: 0611 – June 2011

Recommendation of AWMSG

Valganciclovir (Valcyte[®]) tablets are recommended as an option for use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor.

AWMSG is of the opinion that valganciclovir (Valcyte[®]) tablets are not suitable for shared care within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – Advice no. 0611
Valganciclovir (Valcyte[®]) June 2011